142 related articles for article (PubMed ID: 10843484)
1. Cutaneous fixed drug eruption to paclitaxel; a case report.
Baykal C; Erkek E; Tutar E; Yüce K; Ayhan A
Eur J Gynaecol Oncol; 2000; 21(2):190-1. PubMed ID: 10843484
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-induced cutaneous change mimicking malignancy in a previous cutaneous eruption.
Salas-Martínez AM; Caballero CI; González-Vela MC; Mira MC; Laso-Dosal F; Val-Bernal JF
Rev Esp Patol; 2018; 51(3):188-192. PubMed ID: 30012313
[TBL] [Abstract][Full Text] [Related]
3. [Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].
Lehoczky O; Bagaméri A; Pulay T
Orv Hetil; 2002 Sep; 143(38):2189-91. PubMed ID: 12395475
[TBL] [Abstract][Full Text] [Related]
4. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study.
Kupfer I; Balguerie X; Courville P; Chinet P; Joly P
J Am Acad Dermatol; 2003 Feb; 48(2):279-81. PubMed ID: 12582404
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis.
Winkelmann RR; Yiannias JA; DiCaudo DJ; Trotter SC; Farhey Y; Griffing WL; Martorano LM; Winkelmann JC
Int J Dermatol; 2016 Jan; 55(1):97-100. PubMed ID: 25266415
[No Abstract] [Full Text] [Related]
6. Scleroderma and the taxanes. Is there really a link?
Farrant PB; Mortimer PS; Gore M
Clin Exp Dermatol; 2004 Jul; 29(4):360-2. PubMed ID: 15245529
[TBL] [Abstract][Full Text] [Related]
7. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
8. Generalized pustular dermatosis following paclitaxel therapy.
Weinberg JM; Egan CL; Tangoren IA; Li LJ; Laughinghouse KA; Guzzo CA
Int J Dermatol; 1997 Jul; 36(7):559-60. PubMed ID: 9268763
[No Abstract] [Full Text] [Related]
9. Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption.
Young PC; Montemarano AD; Lee N; Sau P; Weiss RB; James WD
J Am Acad Dermatol; 1996 Feb; 34(2 Pt 1):313-4. PubMed ID: 8642105
[No Abstract] [Full Text] [Related]
10. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
Béhar A; Pujade-Lauraine E; Maurel A; Brun MD; Chauvin FF; Feuilhade de Chauvin F; Oulid-Aissa D; Hille D
Br J Clin Pharmacol; 1997 Jun; 43(6):653-8. PubMed ID: 9205828
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
[TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
13. Severe necrosis due to paclitaxel extravasation.
Herrington JD; Figueroa JA
Pharmacotherapy; 1997; 17(1):163-5. PubMed ID: 9017777
[TBL] [Abstract][Full Text] [Related]
14. A case of paclitaxel-induced pancreatitis.
Kumar DM; Sundar S; Vasanthan S
Clin Oncol (R Coll Radiol); 2003 Feb; 15(1):35. PubMed ID: 12602552
[No Abstract] [Full Text] [Related]
15. [Myocardial infarction after paclitaxel use].
Mersin N; Boulbair F; Davani S; Hehn M; Kantelip JP
Therapie; 2003; 58(5):467-9. PubMed ID: 14682199
[No Abstract] [Full Text] [Related]
16. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
17. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
18. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.
Ostoros G; Pretz A; Fillinger J; Soltesz I; Dome B
Int J Gynecol Cancer; 2006; 16 Suppl 1():391-3. PubMed ID: 16515630
[TBL] [Abstract][Full Text] [Related]
19. Role of weekly paclitaxel in the treatment of advanced ovarian cancer.
Thomas H; Rosenberg P
Crit Rev Oncol Hematol; 2002 Dec; 44 Suppl():S43-51. PubMed ID: 12505598
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Yamada Y; Shirao K; Ohtsu A; Boku N; Hyodo I; Saitoh H; Miyata Y; Taguchi T
Ann Oncol; 2001 Aug; 12(8):1133-7. PubMed ID: 11583196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
